Product details

Subcellular locations

N/A

Swiss Prot

N/A

Gene ID

9262

Modification site

None

Target Protein/Peptide

DRAK2

Applications

IF(IHC-P)

Excitation emission

590nm/617nm

Concentration

1ug per 1ul

Conjugated with

ALEXA FLUOR® 594

Conjugated

Alexa conjugate 1

Applications with corresponding dilutions

IF(IHC-P)(1:50-200)

Clonality

Polyclonal Antibody

Clone

Polyclonal Antibodies

Other name

Anti-DRAK2 Polyclonal

Purification method

Purified by Protein A.

Also known as

DRAK2 Polyclonal Antibody

Group

Polyclonals and antibodies

Type

Conjugated Primary Antibody

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Host organism

Rabbit (Oryctolagus cuniculus)

Properties

For facs or microscopy Alexa 1 conjugate.

Specificity

This antibody reacts specifically with DRAK2

Modification

No modification has been applied to this antibody

Antigen Source

KLH conjugated synthetic peptide derived from human DRAK2

Cross reactive species

Human (Homo sapiens), Mouse (Mus musculus), Rat (Rattus norvegicus)

Storage

Water buffered solution containing 100ug/ml BSA, 50% glycerol and 0.09% sodium azide. Store at 4°C for 12 months.

Description

This antibody needs to be stored at + 4°C in a fridge short term in a concentrated dilution. Freeze thaw will destroy a percentage in every cycle and should be avoided.

About

Polyclonals can be used for Western blot, immunohistochemistry on frozen slices or parrafin fixed tissues. The advantage is that there are more epitopes available in a polyclonal antiserum to detect the proteins than in monoclonal sera.

Cross Reactive Species details

No significant cross reactivity has been observed for this antibody for the tested species. However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species.

Synonyms

DAP kinase related apoptosis inducing protein; DAP kinase related apoptosis inducing protein kinase 2; Death associated protein kinase related 2; DRAK 2; Serine/threonine kinase 17b apoptosis inducing; Serine/threonine kinase 17b; Serine/threonine protein kinase 17B; STK17B; ST17B_HUMAN.

Advisory

Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody, thus reducing its reactivity, specificity and sensitivity. For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube. Prior to use briefly centrifuge the vial to gather all the solution on the bottom.

Background information

Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase related apoptosis inducing protein kinases). DRAKs contain an N terminal kinase domain and a C terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.

Anti-DRAK2 (Polyclonal), ALEXA Fluor 594

Description:

Size: 100 microliters

Catalog no.: GENTObs-3785R-A594

Price: 489 EUR